EuroBiotech—More articles of note

Newspapers

 > Nicox raised €26 million. The French biotech plans to use the cash to advance its pipeline, which includes an ocular itching drug awaiting an FDA approval decision. The investors who participated in the round picked up shares at a price dented by the recent CRL for latanoprostene bunod. Nicox explained its reasoning for raising cash just after the setback in a shareholder letter. Statement I Letter 

> Mapi Pharma completed a $10 million financing round. The Israeli biotech tapped aMoon Fund for the cash, which will go toward a phase 3 trial of Mapi’s reformulation of Teva’s Copaxone. Release

> Kiadis Pharma secured €15 million in debt financing from Kreos Capital. The Dutch biotech has immediately pulled down €10 million and will add the remaining €5 million to its coffers if it can put together a €20 million financing round by July 2018. Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Vectura landed a deal with Dynavax. The agreement clears Dynavax to use Vectura’s nebulizer to administer a TLR9 agonist to lung cancer patients. Release 

> ASIT biotech received regulatory clearance to run a follow-up study featuring patients who participated in its phase 1/2a house dust mite rhinitis trial. Statement

> Vicore Pharma posted data from a phase 1 extension study of its drug C21. The Swedish biotech is advancing into a phase 2a Idiopathic pulmonary fibrosis trial on the strength of the data. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.